Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
With funding from the Ultra-rare Gene-based Therapy Network, scientists at Columbia and the n-Lorem Foundation will create tailor-made gene-based therapies for people with rare forms of ALS.
A study led by Columbia and Cornell researchers finds, surprisingly, that anticoagulants do not prevent recurrent strokes in people with one type of heart condition.
Columbia researchers have identified brain circuits that, when injured, make conscious patients with acute brain injury appear unresponsive, a phenomenon known as hidden consciousness.
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
A study of professionals in the National Hockey League found that players who frequently engaged in fighting on the ice died a decade earlier than less pugilistic players.
Age-related memory loss is caused, in part, by lack of flavanols—nutrients found in certain fruits and vegetables—according to a large study in older adults.
Attending a high school with a high number of teachers with graduate training was the clearest predictor of the impact of school quality on late-life cognition, researchers found.